Evolution of the Average Target: Black Diamond Therapeutics, Inc.

Evolution of the Target Price: Black Diamond Therapeutics, Inc.

Changes in Analyst Recommendations: Black Diamond Therapeutics, Inc.

be1e.g0OilYiVH4U9y0kNmtZ9POV-cQ8MhpW74EFR-0LlHQo.1zfwp-7zJ-p-j3BP17IidKoHH3Zt6fjNgTs5viSDT1zsKcTE3KBz9wyBEA~dd7398e25f6713e6a65fb8df2979a310
03-17 Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating MT
07/08/25 Black Diamond Therapeutics Q2 net loss narrows as costs drop RE
07/03/25 Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating MT
31/07/24 Raymond James Initiates Black Diamond Therapeutics at Outperform MT
16/05/24 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
08/04/24 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
14/07/23 Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
30/06/23 Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
28/06/23 HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
27/06/23 Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
12/05/22 Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
01/04/22 Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
29/03/22 Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
22/03/22 HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
18/03/22 Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
30/09/21 BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
17/08/21 BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
17/08/21 BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
21/05/21 BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
29/03/21 BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
26/03/21 BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
07/01/21 BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
24/11/20 BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+435.71%
+10.28%
+16.98%
+31.88%
+84.16%
+35.46%
+28.51%
-33.36%
-8.27%
+25.55%
Average +62.69%
Weighted average by Cap. +21.55%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%
High Price Target
14.00USD
Spread / Highest target
+660.87%
Low Price Target
7.000USD
Spread / Lowest Target
+280.43%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
HC Wainwright
Piper Sandler
Stifel Nicolaus
Berenberg Bank
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
  4. Consensus Black Diamond Therapeutics, Inc.